Table 2.
Age at menarche, years | |||||
Tumor characteristic | ≤11 | > 11 and ≤13 | > 13 and ≤14 | > 14 | P valuea |
Tumor size | |||||
1–10 mm | 47 (28) | 258 (26) | 183 (27) | 153 (29) | |
11–20 mm | 76 (46) | 414 (43) | 302 (44) | 250 (47) | |
≥21 mm | 43 (26) | 304 (31) | 199 (29) | 129 (24) | 0.188 |
Grade | |||||
Low | 12 (10) | 98 (15) | 66 (14) | 71 (20) | |
Medium | 50 (44) | 270 (40) | 214 (46) | 136 (39) | |
High | 52 (46) | 304 (45) | 188 (40) | 141 (40) | 0.037 |
ER status | |||||
Positive | 91 (73) | 145 (20) | 113 (23) | 302 (79) | |
Negative | 34 (27) | 564 (80) | 381 (77) | 78 (21) | 0.309 |
PR status | |||||
Positive | 84 (69) | 224 (32) | 181 (37) | 252 (68) | |
Negative | 38 (31) | 473 (68) | 305 (63) | 121 (32) | 0.250 |
Lymph node involvement | |||||
Absent | 104 (63) | 630 (66) | 456 (68) | 374 (72) | |
Present | 60 (37) | 329 (34) | 217 (32) | 146 (28) | 0.052 |
Histology | |||||
Ductal | 124 (75) | 692 (71) | 503 (73) | 383 (72) | |
Lobular | 24 (14) | 118 (12) | 78 (11) | 62 (12) | |
All other | 18 (11) | 165 (17) | 108 (16) | 87 (16) | 0.509 |
aPearson chi-square tests of association between groups. ER, estrogen receptor; PR, progesterone receptor.